[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613744":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":36,"locations":10,"responsibleParty":45,"collaborators":47,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":79,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":10},{"fullName":5,"class":6},"Cardiovascular and Interventional Radiological Society of Europe","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adult CLTI patients with infrapopliteal calcified lesions",null,"Adult CLTI patients planned to receive the Esprit BTK™ resorbable scaffold following pre-dilatation with angioplasty balloon.",[13],"Device: Esprit BTK™ Everolimus Eluting Resorbable Scaffold from Abbott",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Esprit BTK™ Everolimus Eluting Resorbable Scaffold from Abbott","The Esprit BTK™ is a bioresorbable vascular scaffold designed for arteries below the knee. It provides temporary support to keep the vessel open while releasing everolimus-an antiproliferative drug that helps prevent excessive tissue growth and reduces the risk of restenosis. As the scaffold delivers the medication, it gradually dissolves, potentially lowering long-term risks associated with permanent stents.",[9],[21],"Drug-eluting resorbable scaffold",[23,27,30,33],{"name":24,"affiliation":25,"role":26},"Gerd Grözinger, Prof. Dr. med.","SLK Kliniken Heilbronn GmbH","STUDY_CHAIR",{"name":28,"affiliation":29,"role":26},"Marianne Brodmann, Univ.-Prof. Dr. med.","Medizinische Universität Graz",{"name":31,"affiliation":32,"role":26},"Raghu Lakshminarayan, Dr","Hull University Teaching Hospital",{"name":34,"affiliation":35,"role":26},"Stefan Müller-Hülsbeck, Prof. Dr. med.","DIAKO Krankenhaus gGmBH",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Claire Poulet, PhD","CONTACT","+41 79 385 16 78","oracue@cirse.org",{"name":43,"role":39,"phone":44,"phoneExt":10,"email":41},"Dhwani S. Korde, PhD","+4367762942469",{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[48],{"name":49,"class":50},"Abbott","INDUSTRY","100613744","resorbable-scaffolds-with-everolimus-elution-for-the-treatment-of-infrapopliteal-artery-disease-in-patients-with-chronic-limb-threatening-ischemia-100613744",false,"NCT07270575","REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia","RESCUE","Inclusion Criteria:\n\n1. Rutherford classification category ≥4;\n2. Treatment of infrapopliteal lesions with the Esprit BTK everolimus eluting resorbable scaffold system following adequate vessel preparation;\n3. Calcification of target lesions must be visible on fluoroscopy or CT-angiography;\n4. Patients competent and willing to provide informed consent.\n\nExclusion Criteria:\n\n1. Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);\n2. Inadequate inflow (\\>30% stenosis) following optimization;\n3. Insufficient direct outflow (less than 1 run-off vessel);\n4. Endovascular procedure(s) on the treatment site within 4 weeks before index procedure;\n5. Patients planned to receive an above ankle amputation of the target limb;\n6. Patients enrolled in ORACLE (ClinicalTrials.gov ID NCT07270562).","ALL","18 Years",{"count":61,"type":62},400,"ESTIMATED","OBSERVATIONAL","RESCUE is a Europe-wide study that will follow 400 people with critical limb-threatening ischemia (CLTI). It aims to see how well Esprit BTK™ Everolimus Eluting Resorbable Scaffolds work in real-life medical settings. The study focuses on people who have heavily calcified arteries in the infrapopliteal areas of the leg.\n\nThese drug-eluting resorbable scaffolds release a medication that helps prevent the inner wall of the blood vessel from thickening after injury or surgery. This can reduce the chance of the artery becoming blocked again (a problem called restenosis), while also giving temporary structural support to the vessel. Over time, the scaffold naturally dissolves in the body, which may lower the long-term risks associated with permanent metal stents.",[66,67],"Chronic Limb Threatening Ischemia","Chronic Limb-Threatening Ischemia",[69,70,71,72,73,21,74,75,76,77,78],"CLTI","Critical Limb-Threatening Ischemia","Infrapopliteal artery disease","Peripheral artery disease","Esprit BTK Everolimus Eluting Resorbable Scaffold","Resorbable vascular scaffold","Real-world evidence study","Patients with infrapopliteal disease","Calcified peripheral artery lesions","Infrapopliteal arteries","NOT_YET_RECRUITING","2026-07-01",{"date":82,"type":83},"2026-07-02","ACTUAL",{"date":85,"type":62},"2026-08",{"date":87,"type":62},"2032-12",{"name":5,"class":6}]